- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.03. | PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls | 3 | Benzinga.com | ||
| 04.03. | PepGen pauses UK arm of DMD trial that's already on hold in US | 1 | FierceBiotech | ||
| 04.03. | PepGen slides after pause on mid-stage Duchenne trial | 1 | Seeking Alpha | ||
| 04.03. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| PEPGEN Aktie jetzt für 0€ handeln | |||||
| 24.02. | PepGen GAAP EPS of -$0.68 beats by $0.04 | 2 | Seeking Alpha | ||
| 24.02. | PepGen Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 24.02. | PepGen Drug Shows Signs of Topping Rivals in Rare Muscle Disease With No Approved Meds | 1 | MedCity News | ||
| 24.02. | PepGen stock price target cut to $14 by Stifel analysts | 1 | Investing.com | ||
| 24.02. | Why PepGen (PEPG) Stock Is Skyrocketing Today | 3 | Benzinga.com | ||
| 24.02. | PepGen Inc. Loss At -$22.24 Mln In Q4 | 1 | RTTNews | ||
| 24.02. | PepGen reports promising DM1 drug trial results | 2 | Investing.com | ||
| 24.02. | PepGen meldet vielversprechende Ergebnisse bei DM1-Medikamententest | 16 | Investing.com Deutsch | ||
| 24.02. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | PepGen Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 29.01. | PepGen continues trials for DMD treatment, addresses safety concerns | 1 | Investing.com | ||
| 29.01. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.24 | PepGen stock down 22% on FDA clinical hold (update) | 1 | Seeking Alpha | ||
| 16.12.24 | Novo builds up manufacturing; Pepgen Duchenne trial put on hold | 14 | BioPharma Dive | ||
| 16.12.24 | PepGen (NASDAQ:PEPG) Stock Rating Lowered by Bank of America | 2 | MarketBeat | ||
| 16.12.24 | FDA hits pause on another of PepGen's muscular dystrophy trials | 2 | FierceBiotech |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,95 | -4,11 % | Übernahmespekulationen und Kaufempfehlungen: Bayer, BioNTech, Evotec, BioNxt Solutions Aktie | Während bei Evotec derzeit die Übernahmespekulationen pausieren, nehmen sie bei BioNxt Solutions Fahrt auf. Das Unternehmen will in den kommenden 60 Tagen wichtige Meilensteine auf dem Weg zur Vermarktung... ► Artikel lesen | |
| CUREVAC | 2,576 | -7,14 % | wO Börsenlounge: Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg gegen Biontech | CureVac hat bestätigt, dass das Europäische Patentamt eine überarbeitete Version seines mRNA-Patents bestätigt hat. Die Entscheidung dürfte Auswirkungen auf den Prozess gegen Biontech haben. Die Aktie... ► Artikel lesen | |
| AMGEN | 287,30 | +1,86 % | Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis | ||
| NOVAVAX | 5,998 | -7,38 % | Novavax Aktie: Dunkelheit vor dem Sturm? | Der Biotechnologiekonzern verzeichnet erhebliche Kursverluste, setzt jedoch auf die Kooperation mit Sanofi als wichtigen Baustein für zukünftige Ertragsquellen und Kostenoptimierung. Die Novavax-Aktie... ► Artikel lesen | |
| BIOGEN | 126,70 | -0,74 % | Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation... ► Artikel lesen | |
| ORGANOVO | 2,650 | 0,00 % | Organovo, Inc.: Organovo Provides Business Update | SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,540 | -3,75 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights | Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-Studie
27.03.2025 / 14:01... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,420 | -5,00 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily
Results Expected in 2H25
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 6,596 | -11,30 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
| GENMAB | 177,70 | -2,15 % | Genmab A/S: TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer | TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,036 | -3,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,880 | -0,79 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,110 | +4,90 % | PacBio Appoints Jim Gibson As New CFO | WASHINGTON (dpa-AFX) - Life science technology company PacBio, Inc. (PACB) announced Thursday the appointment of Jim Gibson as the company's new Chief Financial Officer, effective as of his... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 59,80 | -8,00 % | Sarepta downgraded at RBC Capital on gene therapy concerns |
Das Unternehmen PEPGEN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,69 % bei einem Aktienkurs von 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEPGEN INC finden Sie auf Wallstreet Online.
